NeuroPace, Inc. (NASDAQ:NPCE) Receives $15.00 Average Target Price from Brokerages

Shares of NeuroPace, Inc. (NASDAQ:NPCE) have been assigned an average rating of “Moderate Buy” from the six analysts that are currently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average twelve-month target price among brokerages that have issued a report on the stock in the last year is $15.00.

NPCE has been the topic of a number of recent research reports. JPMorgan Chase & Co. raised their target price on NeuroPace from $9.00 to $14.00 and gave the company an “overweight” rating in a report on Tuesday, December 17th. Wells Fargo & Company dropped their price objective on NeuroPace from $15.00 to $13.00 and set an “overweight” rating on the stock in a research note on Wednesday, November 13th.

Insider Activity

In other news, major shareholder Ltd. Kck sold 223,991 shares of NeuroPace stock in a transaction on Friday, October 25th. The stock was sold at an average price of $5.45, for a total transaction of $1,220,750.95. Following the sale, the insider now directly owns 5,270,845 shares in the company, valued at $28,726,105.25. The trade was a 4.08 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 227,858 shares of company stock valued at $1,244,328 over the last three months. Corporate insiders own 22.20% of the company’s stock.

Institutional Trading of NeuroPace

Large investors have recently added to or reduced their stakes in the stock. Bank of New York Mellon Corp purchased a new position in NeuroPace in the second quarter valued at about $257,000. Rhumbline Advisers bought a new stake in shares of NeuroPace in the 2nd quarter worth approximately $111,000. Acadian Asset Management LLC lifted its stake in NeuroPace by 46.0% in the second quarter. Acadian Asset Management LLC now owns 68,918 shares of the company’s stock valued at $520,000 after purchasing an additional 21,703 shares during the last quarter. XTX Topco Ltd grew its holdings in NeuroPace by 56.1% during the second quarter. XTX Topco Ltd now owns 24,055 shares of the company’s stock valued at $182,000 after purchasing an additional 8,643 shares during the period. Finally, Millennium Management LLC increased its position in NeuroPace by 13.3% in the second quarter. Millennium Management LLC now owns 686,037 shares of the company’s stock worth $5,186,000 after buying an additional 80,324 shares during the last quarter. Hedge funds and other institutional investors own 78.83% of the company’s stock.

NeuroPace Stock Performance

NPCE opened at $11.91 on Tuesday. NeuroPace has a 1-year low of $5.45 and a 1-year high of $18.15. The company has a market cap of $355.51 million, a price-to-earnings ratio of -11.91 and a beta of 2.02. The company’s fifty day moving average price is $10.65 and its two-hundred day moving average price is $8.33. The company has a current ratio of 5.59, a quick ratio of 4.77 and a debt-to-equity ratio of 6.03.

NeuroPace (NASDAQ:NPCE) last posted its earnings results on Tuesday, November 12th. The company reported ($0.19) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.07. The company had revenue of $21.06 million for the quarter, compared to analyst estimates of $19.33 million. NeuroPace had a negative net margin of 36.74% and a negative return on equity of 205.41%. During the same quarter in the prior year, the business posted ($0.28) EPS. On average, analysts expect that NeuroPace will post -1 EPS for the current fiscal year.

NeuroPace Company Profile

NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.